Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Angela Cosey"'
Autor:
Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer
Publikováno v:
Blood Cancer Discovery. 4:118-133
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af15a4e58dc3d2eade0573800002170e
https://doi.org/10.1158/2643-3230.bcd-22-0074
https://doi.org/10.1158/2643-3230.bcd-22-0074
Autor:
Edward A. Stadtmauer, Michael C. Milone, Carl H. June, Jennifer L. Brogdon, Keith G. Mansfield, Dexiu Bu, Regina M. Young, Elizabeth O. Hexner, Gerald P. Linette, Beatriz M. Carreno, Eric Lancaster, Fei Miao, Wesley V. Wilson, Megan Four, Rachel Leskowitz, Kim-Marie Shea, Angela Cosey, Regina Ferthio, Anne Marie Nelson, Andrea Brennan, Don L. Siegel, Gabriela Plesa, Rong Xu, Margaret Patchin, Robert L. Bartoszek, Natalka Koterba, Fang Chen, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, Joseph A. Fraietta, Vanessa E. Gonzalez, Simon F. Lacey, Adam J. Waxman, Dan T. Vogl, Wei-Ting Hwang, Sandra P. Susanibar-Adaniya, Adam D. Cohen, Alfred L. Garfall
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse event
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a41bd0d88d5d4c7b561e5825c554cb6
https://doi.org/10.1158/2643-3230.22546220
https://doi.org/10.1158/2643-3230.22546220
Autor:
Edward A. Stadtmauer, Michael C. Milone, Carl H. June, Jennifer L. Brogdon, Keith G. Mansfield, Dexiu Bu, Regina M. Young, Elizabeth O. Hexner, Gerald P. Linette, Beatriz M. Carreno, Eric Lancaster, Fei Miao, Wesley V. Wilson, Megan Four, Rachel Leskowitz, Kim-Marie Shea, Angela Cosey, Regina Ferthio, Anne Marie Nelson, Andrea Brennan, Don L. Siegel, Gabriela Plesa, Rong Xu, Margaret Patchin, Robert L. Bartoszek, Natalka Koterba, Fang Chen, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, Joseph A. Fraietta, Vanessa E. Gonzalez, Simon F. Lacey, Adam J. Waxman, Dan T. Vogl, Wei-Ting Hwang, Sandra P. Susanibar-Adaniya, Adam D. Cohen, Alfred L. Garfall
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80421cf85e910d57e6c55056f662dc98
https://doi.org/10.1158/2643-3230.c.6551123.v1
https://doi.org/10.1158/2643-3230.c.6551123.v1